Recent progress in vaccine development against chikungunya virus infection
10.3760/cma.j.cn112309-20191012-00325
- VernacularTitle:基孔肯雅病毒感染及疫苗研发最新进展
- Author:
Zhimin ZHAO
1
;
Wenjie TAN
Author Information
1. 中国疾病预防控制中心病毒病预防控制所，卫健委生物安全重点实验室，北京 102206
- From:
Chinese Journal of Microbiology and Immunology
2020;40(6):470-476
- CountryChina
- Language:Chinese
-
Abstract:
Chikungunya virus(CHIKV)is a member of the genus Alphavirus, family Togaviridae and transmitted to humans by Aedes aegypti and Aedes albopictus. It mainly causes Chikungunya fever (CHIKF) with high fever, rash and multiple arthritis/joint pain as the main clinical symptoms, and is a major public health threat of global concern. There is still no vaccine or effective antiviral drug against CHIKV. This review briefly summarized the genomic and epidemiological characteristics of CHIKV, features of immune response to major CHIKV antigens and latest progress in vaccine development.
